معرفی
Dr. Vera Deneer is an Associate Professor of Clinical Pharmacology at the Utrecht Institute for Pharmaceutical Research (UIPS) within the Faculty of Science at Utrecht University, specializing in the Division of Pharmacoepidemiology and Clinical Pharmacology since 2019. She also serves as a hospital pharmacist and clinical pharmacologist at the University Medical Center Utrecht (UMC Utrecht) at the Department of Clinical Pharmacy since 2017. Dr. Deneer holds significant leadership positions including Vice-Chair of the Medicines Evaluation Board (MEB-CBG) since 2019 and Chair of the Dutch Pharmacogenetics Working Group (DPWG).
Dr. Deneer received her PharmD from Utrecht University in 1991 and her PhD from Groningen University in 2003, with research focused on clinical pharmacology and pharmacokinetics of antiarrhythmic drugs in atrial fibrillation. She completed clinical training in hospital pharmacy in 1994 and clinical pharmacology training in 1998. Prior to her current positions, she served as Head of the Pharmacogenetics, Pharmaceutical and Toxicological Laboratory at St. Antonius Hospital, Nieuwegein/Utrecht from 1998 to 2017.
Her research focuses on personalized medicine through the study of biomarkers including genetic variants, patient characteristics, and clinical parameters to optimize drug treatment efficacy and safety. Her work primarily targets cardiovascular disease, lung cancer, and immune-mediated inflammatory diseases. She also investigates clinical reasoning and decision-making by pharmacists to improve medication management in clinical practice. Dr. Deneer serves as principal investigator for multiple research projects funded by The Netherlands Organisation for Health Research and Development.
Dr. Deneer's recent publications demonstrate her leadership in pharmacogenetics guidelines development, with numerous Dutch Pharmacogenetics Working Group (DPWG) guidelines published in 2023-2025 covering gene-drug interactions for various medication classes including antidepressants, antipsychotics, anti-epileptics, and cardiovascular medications. Her work spans both clinical implementation research and educational aspects of pharmacy practice.
Among her significant appointments, Dr. Deneer serves as Vice-Chair of the Medicines Evaluation Board (MEB-CBG) and Chair of the Dutch Pharmacogenetics Working Group (DPWG). She previously chaired a medical research ethics committee from 2012-2017 and serves on multiple national and hospital committees related to pharmacotherapy and drug safety.
Dr. Deneer has been actively involved in mentoring pharmacy students and professionals, with recent publications focusing on clinical decision-making education for pharmacists. Her work bridges the gap between pharmacogenetic research and clinical implementation, with particular emphasis on optimizing drug treatment strategies for individual patients while minimizing adverse drug reactions.
